773877-44-4

Usage

Uses

Used in Pharmaceutical Industry:
1,3-DIMETHYL-2,4-DIOXO-1,2,3,4-TETRAHYDRO-QUINAZOLINE-6-SULFONYL CHLORIDE is used as a synthetic reagent for the preparation of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 1,3-DIMETHYL-2,4-DIOXO-1,2,3,4-TETRAHYDRO-QUINAZOLINE-6-SULFONYL CHLORIDE is employed as a reagent in the synthesis of agrochemicals. Its incorporation aids in the creation of compounds designed to protect crops and enhance agricultural productivity.
Safety Precautions:
Given its high reactivity and potential hazards, 1,3-DIMETHYL-2,4-DIOXO-1,2,3,4-TETRAHYDRO-QUINAZOLINE-6-SULFONYL CHLORIDE must be handled with extreme care in a controlled laboratory environment. Appropriate safety measures, including the use of personal protective equipment and adherence to established laboratory protocols, are essential to mitigate risks associated with its use.

Upstream product

• 1134967-52-4 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonic acid 
• 1013-01-0 1,3-dimethyl-1H-quinazoline-2,4-dione 
• 604-50-2 glycosmicine 

Relevant academic research and scientific papers

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design. 1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors.

Synthesis and characterization of the first inhibitor of: N -acylphosphatidylethanolamine phospholipase D (NAPE-PLD)

N-Acylphosphatidylethanolamine phospholipase D (NAPE-PLD) is a membrane-associated zinc enzyme that catalyzes the hydrolysis of N-acylphosphatidylethanolamines (NAPEs) into fatty acid ethanolamides (FAEs). Here, we describe the identification of the first small-molecule NAPE-PLD inhibitor, the quinazoline sulfonamide derivative 2,4-dioxo-N-[4-(4-pyridyl)phenyl]-1H-quinazoline-6-sulfonamide, ARN19874.

2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

Quinazolines 1. Synthesis and chemical reactions of 6-chlorosulfonyl- quinazoline-2,4-diones

Treatment of quinazoline-2,4-dione and its symmetrical 1,3-dialkyl derivatives with chlorosulfonic acid gave the corresponding 6- chlorosulfonylquinazoline-2,4-diones. Reaction of the compounds obtained with nucleophilic agents (water, ammonia, aliphatic and cyclic amines) gave the corresponding free 2,4-dioxoquinazoline-6-sulfonic acids, 6- sulfamidoquinazoline-2,4-diones, and 2,4-dioxoquinazoline-6-sulfonic acid amides.